← SearchA PHASE 1C STUDY OF PROSETIN, A NOVEL, BRAIN-PENETRANT MAP4K INHIBITOR, IN PARTICIPANTS WITH ALS$2,180,261FY2025Defense Health AgencyDODProjenx IncInvestigatorsView source on USAspending →